Pharma channel feed

Got­tlieb seeks new com­par­a­tive ap­proval stan­dard for opi­oids

7 years ago

Months af­ter Imfinzi com­bo flops, As­traZeneca wins NICE en­dorse­ment as lung can­cer monother­a­py

7 years ago

We de­stroyed near­ly 8,000 packs of ex­pired Orkam­bi stock last year, Ver­tex tells UK MPs

7 years ago

FDA’s On­col­o­gy Cen­ter of Ex­cel­lence touts 2018 ac­com­plish­ments

7 years ago

Ab­b­Vie gets its first ap­proval for a drug ex­ecs be­lieve could be worth up to $5B in an­nu­al sales

7 years ago

Eli Lil­ly joins a troi­ka of Big Phar­mas that have tied up to a low-pro­file biotech with big as­pi­ra­tions in au­toim­mune dis­ease, can­cer

7 years ago

Block­buster to be? No­var­tis snags a ma­jor win as FDA OKs a top PhI­II drug -- will a pric­ing con­tro­ver­sy fol­low?

7 years ago

The top 10 Alzheimer's deals tell us a lot about a big change of di­rec­tion for a dis­as­ter-prone field

7 years ago
R&D

FTC de­mands more in­fo from Bris­tol-My­ers, Cel­gene on pso­ri­a­sis drugs, sig­nal­ing a po­ten­tial hitch for $74B deal

7 years ago
Deals

Aim­mune's peanut al­ler­gy im­munother­a­py clears Eu­ro­pean PhI­II with fly­ing col­ors, paving way for first US, EU ther­a­peu­tic ap­proval

7 years ago
R&D

Hu­malog's list price may have gone up, but Lil­ly says it got paid less per sale in 2018 ver­sus 2014

7 years ago

Price hikes, a strate­gic re­treat and 1 big new ap­proval has shak­en up the rank­ings of the 20 most ex­pen­sive drugs on the plan­et

7 years ago

FDA snubs Sanofi, Lex­i­con on their pitch for SGLT1/2 di­a­betes drug so­tagliflozin, com­pa­nies mum on what went wrong

7 years ago

As gener­ic en­try looms for its cash cow, Jazz wins FDA nod for fol­low-up sleep dis­or­der drug

7 years ago

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
R&D

EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

7 years ago

With eye on rev­enue sta­bi­liza­tion, Gilead takes 4.9% hike on a bas­ket of drugs

7 years ago

Pfiz­er lines up a po­ten­tial $687M rare dis­ease buy­out to ex­pand its stake in the hot gene ther­a­py field

7 years ago
Cell/Gene Tx

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

7 years ago

FDA ap­proves trail­blaz­ing post­par­tum de­pres­sion ther­a­py, in cru­cial mile­stone for wom­en's health

7 years ago

Skin re­gen­er­a­tion com­pa­ny Po­lar­i­tyTE re­veals SEC in­ves­ti­ga­tion, prob­ing in­to its lead prod­uct, for­mer CFO and cur­rent in­vestors

7 years ago

Roche stacks up Tecen­triq nods, fol­low­ing up breast can­cer ap­proval with small cell lung can­cer

7 years ago

Bio­haven is bet­ting hun­dreds of mil­lions it can hus­tle ahead of ri­vals in a block­buster race. A quick M&A deal could pay off back­ers big time

7 years ago

Scott Got­tlieb to bio­phar­ma: You want­ed us to help mod­ern­ize R&D, now go out and do it

7 years ago
First page Previous page 279280281282283284285 Next page Last page
A service from the Financial Times